Netherlands· NL-ba8ce431639b

Enhertu 100 mg, poeder voor concentraat voor oplossing voor infusie

A trastuzumab deruxtecan product containing trastuzumab deruxtecan, registered in Netherlands by DAIICHI SANKYO EUROPE GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC L01FD04

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about trastuzumab deruxtecanAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Trastuzumab deruxtecan is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FD04 (trastuzumab deruxtecan), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search trastuzumab deruxtecan products by name

Trastuzumab deruxtecan · ATC L01FD04

12 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of trastuzumab deruxtecan costs, country by country.

Normalised to the WHO defined daily dose (18 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Trastuzumab deruxtecan · price per daily dose (18 mg)

USD · FX 28 Sept 2026

CH Switzerland$337.42

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: TRASTUZUMAB DERUXTECAN
Manufacturer: DAIICHI SANKYO EUROPE GmbH
Country: Netherlands (NL)
ATC code: L01FD04
ATC class: Trastuzumab deruxtecan
Defined daily dose: 18 mg, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/20/1508

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

61 interactions on record for trastuzumab deruxtecan.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check trastuzumab deruxtecan against other medicines How interaction checks work

Trastuzumab deruxtecan · interactions on record

61 records

28 severe
33 moderate

Most severe, free to view

CladribineL01BB04severe
Talimogene laherparepvecL01XL02severe
Talimogen laherparepvecL01XX51severe
LeflunomidL04AA13severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Trastuzumab deruxtecan in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All trastuzumab deruxtecan products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Enhertu
Liechtenstein · Enhertu
Norway · Enhertu

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/2547a833-3bcd-4e46-8237-b2c834c9446f
GET /v1/drugs/2547a833-3bcd-4e46-8237-b2c834c9446f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Trastuzumab deruxtecan",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126828",
  "excipients": [
    "HISTIDINE, (L-)",
    "HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
    "POLYSORBAAT 80 (E 433)",
    "SACCHAROSE"
  ],
  "substances": [
    "TRASTUZUMAB DERUXTECAN"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/01/18",
  "procedure_number": "EMEA/H/C/005124",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1508",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about trastuzumab deruxtecan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console